全球子宫肌瘤市场-2022-2029

市场动态

全球子宫肌瘤市场的增长是由子宫肌瘤患病率上升以及对诊断和治疗子宫疾病的需求不断增加推动的。子宫肌瘤及相关疾病患者数量的增加，微创手术的增加，以及用于安全有效的子宫肌瘤切除术的技术先进设备的采用率不断提高，预计将推动市场。我在这里。

对子宫疾病诊断和治疗的需求不断增长推动市场增长

肌瘤是女性最常见的盆腔肿瘤，全球患病率为 21.4%。大约 20% 到 80% 的女性在 50 岁时会患上子宫肌瘤。子宫肌瘤在 40 多岁和 50 岁出头的女性中很常见。大约 80% 的非裔美国女性会在 50 岁时患上子宫肌瘤。随着女性年龄的增长，她们更容易出现荷尔蒙失调、子宫异常出血、月经不调等妇科问题。 2017 年发表的另一项研究包括大约 5,000 名患有子宫肌瘤的意大利女性，发现 95% 的手术包括 36-55 岁的女性。此外，由于并发症更少和住院时间更短，微创手术的使用增加也有望推动市场增长。技术进步，例如越来越多地使用机器人手术和腹腔镜辅助手术来实现高质量和高效的治疗，也可能有助于肌瘤手术市场的增长。

由于子宫肌瘤摘除术的增加，技术先进产品的推出有望推动市场增长。诸如腹腔镜诱导和机器人辅助肌瘤摘除术等技术进步已证明非切口手术可用于治疗肌瘤，且无副作用或副作用极小。与开腹手术相比，腹腔镜子宫肌瘤摘除术出血少、并发症少、住院时间短、恢復正常生活快。因此，使用机器人进行子宫肌瘤摘除术具有优于传统腹腔镜手术（开放手术）的几个优点，并且在生殖手术领域被广泛接受和采用。

与子宫肌瘤相关的并发症阻碍市场增长

但是，子宫肌瘤摘除术与出血、感染、肠梗阻、粘连形成、肠/膀胱/输卵管/输尿管损伤、伤口感染和伤口脱离有关。由于症状復发，大约 20% 到 25% 接受过子宫肌瘤切除术的人需要再次进行盆腔手术，通常是子宫切除术。肌瘤的复发很常见，尤其是在患有多发性肌瘤的患者中。单发肌瘤患者的复发率为27%，多发肌瘤患者的复发率为59%。接受肌瘤切除术的患者应在手术前告知这些风险，并了解可能无法进行肌瘤切除术。

COVID-19 影响分析

COVID-19 大流行对子宫肌瘤市场的影响是巨大的。随着全球 COVID-19 病例数量激增，医疗保健服务将资源重新分配给患有 COVID-19 的患者。提供了大流行期间患者管理的指南和建议。因此，医院优先考虑紧急护理，并推迟或推迟肌瘤切除术等选择性手术，导致等待手术的患者等待时间较长。 2020 年 CovidSurg 合作研究估计，在 COVID-19 造成的为期 12 週的中断高峰期间，约有 2800 万例手术（包括 81.7% 的良性手术）将被推迟。随着病情恢復正常，预计子宫肌瘤会逐渐恢復。

全球子宫肌瘤手术市场报告将提供对大约 40 多个市场数据表、45 多个数字和 190 页的覆盖范围的访问。

内容

第 1 章全球子宫肌瘤市场的研究方法和范围

• 调查方法
• 调查目的和范围

第 2 章全球子宫肌瘤市场 - 市场定义和概述

第 3 章全球子宫切除术市场执行摘要

• 按类型划分的市场细分
• 按产品划分的市场细分
• 最终用户的市场细分
• 按地区划分的市场细分

第 4 章全球子宫肌瘤市场 - 市场动态

• 市场影响因素
  • 驱动程序
    • 子宫疾病诊治需求上升
    • 微创手术的兴起
  • 约束因素
    • 与子宫肌瘤摘除术相关的并发症
  • 商机
  • 影响分析

第 5 章全球子宫肌瘤市场 - 行业分析

• 波特五力分析
• 供应链分析
• 监管分析

第 6 章全球子宫肌瘤市场 - COVID-19 分析

• COVID-19 的市场分析
  • COVID-19 之前的市场情景
  • COVID-19 的当前市场情景
  • COVID-19 后或未来情景
• COVID-19 期间的价格动态
• 供需产品
• 大流行期间与市场相关的政府举措
• 製造商的战略举措
• 总结

第 7 章全球子宫肌瘤摘除市场 - 按类型

• 腹腔镜
• 腹腔镜
• 宫腔镜检查
• 机器人

第 8 章全球子宫肌瘤摘除市场-按产品

• 腹腔镜动力粉碎机
• 腹腔镜封口机
• 谐音女
• 其他

第 9 章全球子宫肌瘤市场 - 按最终用户分类

• 医院和诊所
• 手术中心
• 其他

第 10 章全球子宫肌瘤摘除市场 - 按地区划分

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 11 章全球子宫肌瘤市场 - 竞争格局

• 主要发展和战略
• 公司份额分析
• 产品基准

第 12 章全球子宫肌瘤市场 - 公司简介

• Medtronic PLC
  • 公司概况
  • 产品组合和描述
  • 主要亮点
  • 财务摘要
• Stryker Corporation
• ConMed Corporation
• INSIGHTEC Ltd
• CooperSurgical Inc.
• Hologic Inc.
• Intuitive Surgical Inc.
• KARL STORZ SE & Co. KG
• B Braun
• Richard Wolf Medical Instruments

第 13 章全球子宫肌瘤摘除术市场-DataM

Market Overview

The Global Myomectomy Market is expected to grow at a high CAGR of 9.1% during the forecasting period (2022-2029).

Myomectomy is a surgical procedure to remove uterine fibroids. These common non-cancerous growths in the uterus of women at their childbearing age, cause symptoms such as heavy bleeding during the menstrual cycle, increased menstrual cramping, pain in the pelvis or lower back, and swelling enlargement of the abdomen. Myomectomy preserves the chances of women getting pregnant.

Market Dynamics

The global myomectomy market growth is driven by the rising prevalence of uterine fibroids and the growing demand for the diagnosis and treatment of uterine disorders. The increasing number of patients suffering from uterine fibroids and associated conditions, the growing number of less invasive procedures, and the rising adoption of technologically advanced devices for safe and effective myomectomy procedures are the major factors expected to drive the market.

The growing demand for diagnosis and treatment of uterine disorder will drive the market growth

Uterine fibroids are the most common pelvic tumors in women, occurring globally with a prevalence of 21.4%. About 20% to 80% of women develop fibroids by the time they reach age 50. Fibroids are common in women in their 40s and early 50s. About 80% of African American women will develop fibroids by the age of 50. The increasing female aging population is propelling the growth of the market as the elderly population is more susceptible to gynecological problems, such as hormonal imbalance, abnormal uterine bleeding, and irregular menstrual cycle, which is fueling the demand for the global myomectomy market. Another research study published in 2017, which included approximately 5,000 Italian women with uterine fibroids, showed that 95% of the surgeries performed included women in the age group of 36-55 years. Additionally, a rise in the number of minimally invasive surgical procedures due to fewer complications and reduced hospital stay is anticipated to drive the growth of the market. Technological advancements, such as the rise in the number of robotic and laparoscopic-assisted surgeries to deliver quality and efficient treatment, may also contribute to the growth of the myomectomy market.

The launch of technologically advanced products due to the increasing number of myomectomy procedures for uterine fibroids is likely to boost the market growth. Technological advancements such as the introduction of laparoscopic or robotically assisted myomectomy procedures have shown incisionless surgery with no or minimal side effects for fibroids treatment. As compared to the open abdominal myomectomy surgery, with robotic myomectomy patient experience less blood loss with fewer complication rates, have a shorter hospital stay, and returns to normal activities more quickly. Thus, the use of robots for myomectomy surgery and their several advantages over conventional laparoscopy (open surgery), have been widely accepted and incorporated into the field of reproductive surgery.

The complications associated with myomectomy will hamper the growth of the market

However, myomectomy is associated with hemorrhage, infection, bowel obstruction, adhesion formation, damage to the bowel, bladder, fallopian tube, ureter, wound infection, and wound separation. About 20-25% of patients undergoing myomectomy require another pelvic operation, usually hysterectomy because of recurrence of symptoms. Recurrent myomas are common, especially in patients with multiple myomas. Patients with a solitary myoma have a 27% recurrence rate, and those with multiple myomas have a rate of 59%. Patients undergoing myomectomy should be counseled pre-operatively about these risks and must understand that myomectomy may not be possible.

COVID-19 Impact Analysis

The impact of the COVID-19 pandemic is significant on the myomectomy market. With the surge of COVID-19 cases across the world, healthcare services diverted their resources toward the patients suffering from COVID-19. Guidelines and recommendations were provided for the management of patients during the pandemic. This resulted in hospitals prioritizing emergency procedures and delaying or postponing elective procedures, such as myomectomy surgery, leading to a backlog of patients waiting for their surgeries for months. A CovidSurg Collaborative study, 2020, estimated that around 28 million operations would be delayed during the peak 12-week disruption due to COVID-19, including 81.7% benign surgeries. With conditions returning to normal, myomectomy procedures are expected to recover gradually.

Segment Analysis

The abdominal segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The abdominal segment, also known as the open type, is considered the classic myomectomy surgery. This procedure is performed by making a small horizontal incision (or a vertical incision for a larger uterus) across the abdomen region of the body. With the rise in the number of patients with uterine fibroids, the demand for myomectomy procedures may also increase. Abdominal myomectomy is the highly performed and preferred type of treatment. A 2017 UK research study published on Gynecological Surgery, Springer Open, involving physician consultants, identifies that nearly 70% of them perform open myomectomy. The open type is preferred based on the size and location of fibroids. Hence, due to such activities across different countries, the number of procedures is expected to grow further over the forecast period.

Geographical Analysis

North America region holds the largest market share of the global myomectomy market

North America dominates the market for myomectomy and is expected to show a similar trend over the forecast period, owing to the rising prevalence of uterine fibroid. A 2018 article published in the American Journal of Obstetrics and Gynecology shows that the prevalence of uterine fibroids was found to be 10% in the United States, with higher occurring rates observed for black women and other ethnic or racial groups. Additionally, according to the World Economic Outlook 2021 by IMF, real GDP is projected to grow by 6.4% in the United States and 5% in Canada. These factors, coupled with high reimbursement rates and government initiatives, contribute to North America occupying the largest share of the overall myomectomy market.

The increased patient pool undergoing hormonal disorders and increasing prevalence of uterine cancer is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at the age of 35, which increased to more than 80% by the age of 50 years among women.

Also, the adoption of minimally invasive and effective alternatives to open surgeries and technological advancements in devices with an increase in regulatory approvals and favorable reimbursement policies are expected to boost the growth of the myomectomy market in this region.

Competitive Landscape

The myomectomy market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Medtronic PLC, Stryker Corporation, ConMed Corporation, INSIGHTEC Ltd, CooperSurgical Inc., Hologic Inc., Intuitive Surgical Inc., KARL STORZ SE & Co. KG, B Braun, Richard Wolf Medical Instruments among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Myomectomy Market globally. For instance, in August 2020, Hologic Inc. announced the acquisition of Acessa Health Inc., a privately held company focused on minimally invasive therapies for fibroids. This acquisition is anticipated to strengthen Hologic's fibroid treatment product portfolio.

Medtronic plc

Overview:

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical-Surgical Portfolio, and Diabetes Operating Unit.

Product Portfolio:

Veriset Hemostatic Patch: The Veriset patch is designed to address the unmet need for a simple to use, fast, and highly effective hemostatic patch. Medtronic launched the Veriset patch. It is designed to help to achieve hemostasis quickly and consistently, in ~1 minute.

Why Purchase the Report?

Visualize the composition of the global myomectomy market segmentation by type, product, end-user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global myomectomy market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global myomectomy market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global myomectomy market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 190 pages.

Table of Contents

1. Global Myomectomy Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Global Myomectomy Market -Market Definition and Overview

3. Global Myomectomy Market - Executive Summary

• 3.1. Market Snippet By Type
• 3.2. Market snippet By Product
• 3.3. Market Snippet By End User
• 3.4. Market Snippet by Region

4. Global Myomectomy Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The growing demand for diagnosis and treatment of the uterine disorder
    • 4.1.1.2. Rise in Minimally Invasive Procedures
  • 4.1.2. Restraints:
    • 4.1.2.1. The complications associated with myomectomy
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Global Myomectomy Market - Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis

6. Global Myomectomy Market - COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Product
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. Global Myomectomy Market - By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  • 7.1.2. Market Attractiveness Index, By Type Segment
• 7.2. Laparoscopic*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Abdominal
• 7.4. Hysteroscopic
• 7.5. Robotic

8. Global Myomectomy Market - By Product

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 8.1.2. Market Attractiveness Index, By Product
• 8.2. Laparoscopic Power Morcellators*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Laparoscopic Sealer
• 8.4. Harmonic Scalpel
• 8.5. Others

9. Global Myomectomy Market - By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User Segment
• 9.2. Hospitals & Clinics *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Surgical Centers
• 9.4. Other

10. Global Myomectomy Market - By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Myomectomy Market - Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Global Myomectomy Market - Company Profiles

• 12.1. Medtronic PLC*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Stryker Corporation
• 12.3. ConMed Corporation
• 12.4. INSIGHTEC Ltd
• 12.5. CooperSurgical Inc.
• 12.6. Hologic Inc.
• 12.7. Intuitive Surgical Inc.
• 12.8. KARL STORZ SE & Co. KG
• 12.9. B Braun
• 12.10. Richard Wolf Medical Instruments

LIST NOT EXHAUSTIVE

13. Global Myomectomy Market - DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us